VEGFR2 blockade augments the effects of tyrosine kinase inhibitors by inhibiting angiogenesis and oncogenic signaling in oncogene‐driven non‐small‐cell lung cancers

Molecular agents targeting the epidermal growth factor receptor (EGFR)‐, anaplastic lymphoma kinase (ALK)‐ or c‐ros oncogene 1 (ROS1) alterations have revolutionized the treatment of oncogene‐driven non‐small‐cell lung cancer (NSCLC). However, the emergence of acquired resistance remains a significa...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:Cancer Sci
Κύριοι συγγραφείς: Watanabe, Hiromi, Ichihara, Eiki, Kayatani, Hiroe, Makimoto, Go, Ninomiya, Kiichiro, Nishii, Kazuya, Higo, Hisao, Ando, Chihiro, Okawa, Sachi, Nakasuka, Takamasa, Kano, Hirohisa, Hara, Naofumi, Hirabae, Atsuko, Kato, Yuka, Ninomiya, Takashi, Kubo, Toshio, Rai, Kammei, Ohashi, Kadoaki, Hotta, Katsuyuki, Tabata, Masahiro, Maeda, Yoshinobu, Kiura, Katsuyuki
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: John Wiley and Sons Inc. 2021
Θέματα:
Original Articles
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8088971/
https://ncbi.nlm.nih.gov/pubmed/33410241
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.14801
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια